A Novel Mechanism Underlying Antiviral Activity of an Influenza Virus M2-Specific Antibody

Protective immunity against influenza A viruses (IAVs) generally depends on antibodies to the major envelope glycoprotein, hemagglutinin (HA), whose antigenicity is distinctive among IAV subtypes. On the other hand, the matrix 2 (M2) protein is antigenically highly conserved and has been studied as...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of virology 2020-12, Vol.95 (1)
Hauptverfasser: Manzoor, Rashid, Eguchi, Nao, Yoshida, Reiko, Ozaki, Hiroichi, Kondoh, Tatsunari, Okuya, Kosuke, Miyamoto, Hiroko, Takada, Ayato
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page
container_title Journal of virology
container_volume 95
creator Manzoor, Rashid
Eguchi, Nao
Yoshida, Reiko
Ozaki, Hiroichi
Kondoh, Tatsunari
Okuya, Kosuke
Miyamoto, Hiroko
Takada, Ayato
description Protective immunity against influenza A viruses (IAVs) generally depends on antibodies to the major envelope glycoprotein, hemagglutinin (HA), whose antigenicity is distinctive among IAV subtypes. On the other hand, the matrix 2 (M2) protein is antigenically highly conserved and has been studied as an attractive vaccine antigen to confer cross-protective immunity against multiple subtypes of IAVs. However, antiviral mechanisms of M2-specific antibodies are not fully understood. Here, we report the molecular basis of antiviral activity of an M2-specific monoclonal antibody (MAb), rM2ss23. We first found that rM2ss23 inhibited A/Aichi/2/1968 (H3N2) (Aichi) but not A/PR/8/1934 (H1N1) (PR8) replication. rM2ss23 altered the cell surface distribution of M2, likely by cross-linking the molecules, and interfered with the colocalization of HA and M2, resulting in reduced budding of progeny viruses. However, these effects were not observed for another strain, PR8, despite the binding capacity of rM2ss23 to PR8 M2. Interestingly, HA was also involved in the resistance of PR8 to rM2ss23. We also found that two amino acid residues at positions 54 and 57 in the M2 cytoplasmic tail were critical for the insensitivity of PR8 to rM2ss2. These findings suggest that the disruption of the M2-HA colocalization on infected cells and subsequent reduction of virus budding is one of the principal mechanisms of antiviral activity of M2-specific antibodies and that anti-M2 antibody-sensitive and -resistant IAVs have different properties in the interaction between M2 and HA. Although the IAV HA is the major target of neutralizing antibodies, most of the antibodies are HA subtype specific, restricting the potential of HA-based vaccines. On the contrary, the IAV M2 protein has been studied as a vaccine antigen to confer cross-protective immunity against IAVs with multiple HA subtypes, since M2 is antigenically conserved. Although a number of studies highlight the protective role of anti-HA neutralizing and nonneutralizing antibodies, precise information on the molecular mechanism of action of M2-specific antibodies is still obscure. In this study, we found that an anti-M2 antibody interfered with the HA-M2 association, which is important for efficient budding of progeny virus particles from infected cells. The antiviral activity was IAV strain dependent despite the similar binding capacity of the antibody to M2, and, interestingly, HA was involved in susceptibility to the antibody. Our
doi_str_mv 10.1128/jvi.01277-20
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7737731</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2451855692</sourcerecordid><originalsourceid>FETCH-LOGICAL-c537t-7901a1faad9b5e6c7a1b55f4fda0b712a73031e4ffad85a3a7c1d363fbb8480e3</originalsourceid><addsrcrecordid>eNpVkctLAzEQxoMoWh83z5KjB7dmkk2zvQil-Kj4OGhFvITZbKKRbbZudgv1r3fVKgoDMzC_-eZjhpB9YH0Anh2_LnyfAVcq4WyN9IANs0RKSNdJjzHOEymyxy2yHeMrY5Cmg3STbAnBpOQSeuRpRG-qhS3ptTUvGHyc0WkobF0ufXimo9D4ha-xpCPzWTVLWjmKgU6CK1sb3pE--LqN9Jond3NrvPPmayiviuUu2XBYRru3yjtkenZ6P75Irm7PJ-PRVWKkUE2ihgwQHGIxzKUdGIWQS-lSVyDLFXBUggmwqXNYZBIFKgOFGAiX51maMSt2yMm37rzNZ7YwNjSdYz2v_Qzrpa7Q6_-d4F_0c7XQSokuoBM4XAnU1VtrY6NnPhpblhhs1UbNUwmZlIMh79Cjb9TUVYy1db9rgOnPd-jLh4n-eofmrMMP_lr7hX_uLz4AI66Hkw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2451855692</pqid></control><display><type>article</type><title>A Novel Mechanism Underlying Antiviral Activity of an Influenza Virus M2-Specific Antibody</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Manzoor, Rashid ; Eguchi, Nao ; Yoshida, Reiko ; Ozaki, Hiroichi ; Kondoh, Tatsunari ; Okuya, Kosuke ; Miyamoto, Hiroko ; Takada, Ayato</creator><contributor>Heise, Mark T.</contributor><creatorcontrib>Manzoor, Rashid ; Eguchi, Nao ; Yoshida, Reiko ; Ozaki, Hiroichi ; Kondoh, Tatsunari ; Okuya, Kosuke ; Miyamoto, Hiroko ; Takada, Ayato ; Heise, Mark T.</creatorcontrib><description>Protective immunity against influenza A viruses (IAVs) generally depends on antibodies to the major envelope glycoprotein, hemagglutinin (HA), whose antigenicity is distinctive among IAV subtypes. On the other hand, the matrix 2 (M2) protein is antigenically highly conserved and has been studied as an attractive vaccine antigen to confer cross-protective immunity against multiple subtypes of IAVs. However, antiviral mechanisms of M2-specific antibodies are not fully understood. Here, we report the molecular basis of antiviral activity of an M2-specific monoclonal antibody (MAb), rM2ss23. We first found that rM2ss23 inhibited A/Aichi/2/1968 (H3N2) (Aichi) but not A/PR/8/1934 (H1N1) (PR8) replication. rM2ss23 altered the cell surface distribution of M2, likely by cross-linking the molecules, and interfered with the colocalization of HA and M2, resulting in reduced budding of progeny viruses. However, these effects were not observed for another strain, PR8, despite the binding capacity of rM2ss23 to PR8 M2. Interestingly, HA was also involved in the resistance of PR8 to rM2ss23. We also found that two amino acid residues at positions 54 and 57 in the M2 cytoplasmic tail were critical for the insensitivity of PR8 to rM2ss2. These findings suggest that the disruption of the M2-HA colocalization on infected cells and subsequent reduction of virus budding is one of the principal mechanisms of antiviral activity of M2-specific antibodies and that anti-M2 antibody-sensitive and -resistant IAVs have different properties in the interaction between M2 and HA. Although the IAV HA is the major target of neutralizing antibodies, most of the antibodies are HA subtype specific, restricting the potential of HA-based vaccines. On the contrary, the IAV M2 protein has been studied as a vaccine antigen to confer cross-protective immunity against IAVs with multiple HA subtypes, since M2 is antigenically conserved. Although a number of studies highlight the protective role of anti-HA neutralizing and nonneutralizing antibodies, precise information on the molecular mechanism of action of M2-specific antibodies is still obscure. In this study, we found that an anti-M2 antibody interfered with the HA-M2 association, which is important for efficient budding of progeny virus particles from infected cells. The antiviral activity was IAV strain dependent despite the similar binding capacity of the antibody to M2, and, interestingly, HA was involved in susceptibility to the antibody. Our data provide a novel mechanism underlying antiviral activity of M2-specific antibodies.</description><identifier>ISSN: 0022-538X</identifier><identifier>EISSN: 1098-5514</identifier><identifier>DOI: 10.1128/jvi.01277-20</identifier><identifier>PMID: 33055251</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Amino Acids ; Animals ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - metabolism ; Antibodies, Viral - immunology ; Antibodies, Viral - pharmacology ; Antiviral Agents - immunology ; Antiviral Agents - pharmacology ; Dogs ; HEK293 Cells ; Hemagglutinin Glycoproteins, Influenza Virus - metabolism ; Humans ; Influenza A virus - drug effects ; Influenza A virus - genetics ; Influenza A virus - immunology ; Madin Darby Canine Kidney Cells ; Mutation ; Protein Binding - drug effects ; Species Specificity ; Vaccines and Antiviral Agents ; Viral Matrix Proteins - chemistry ; Viral Matrix Proteins - genetics ; Viral Matrix Proteins - immunology ; Viral Matrix Proteins - metabolism ; Virus Release - drug effects</subject><ispartof>Journal of virology, 2020-12, Vol.95 (1)</ispartof><rights>Copyright © 2020 American Society for Microbiology.</rights><rights>Copyright © 2020 American Society for Microbiology. 2020 American Society for Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c537t-7901a1faad9b5e6c7a1b55f4fda0b712a73031e4ffad85a3a7c1d363fbb8480e3</citedby><cites>FETCH-LOGICAL-c537t-7901a1faad9b5e6c7a1b55f4fda0b712a73031e4ffad85a3a7c1d363fbb8480e3</cites><orcidid>0000-0002-7987-9884</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737731/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737731/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33055251$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Heise, Mark T.</contributor><creatorcontrib>Manzoor, Rashid</creatorcontrib><creatorcontrib>Eguchi, Nao</creatorcontrib><creatorcontrib>Yoshida, Reiko</creatorcontrib><creatorcontrib>Ozaki, Hiroichi</creatorcontrib><creatorcontrib>Kondoh, Tatsunari</creatorcontrib><creatorcontrib>Okuya, Kosuke</creatorcontrib><creatorcontrib>Miyamoto, Hiroko</creatorcontrib><creatorcontrib>Takada, Ayato</creatorcontrib><title>A Novel Mechanism Underlying Antiviral Activity of an Influenza Virus M2-Specific Antibody</title><title>Journal of virology</title><addtitle>J Virol</addtitle><description>Protective immunity against influenza A viruses (IAVs) generally depends on antibodies to the major envelope glycoprotein, hemagglutinin (HA), whose antigenicity is distinctive among IAV subtypes. On the other hand, the matrix 2 (M2) protein is antigenically highly conserved and has been studied as an attractive vaccine antigen to confer cross-protective immunity against multiple subtypes of IAVs. However, antiviral mechanisms of M2-specific antibodies are not fully understood. Here, we report the molecular basis of antiviral activity of an M2-specific monoclonal antibody (MAb), rM2ss23. We first found that rM2ss23 inhibited A/Aichi/2/1968 (H3N2) (Aichi) but not A/PR/8/1934 (H1N1) (PR8) replication. rM2ss23 altered the cell surface distribution of M2, likely by cross-linking the molecules, and interfered with the colocalization of HA and M2, resulting in reduced budding of progeny viruses. However, these effects were not observed for another strain, PR8, despite the binding capacity of rM2ss23 to PR8 M2. Interestingly, HA was also involved in the resistance of PR8 to rM2ss23. We also found that two amino acid residues at positions 54 and 57 in the M2 cytoplasmic tail were critical for the insensitivity of PR8 to rM2ss2. These findings suggest that the disruption of the M2-HA colocalization on infected cells and subsequent reduction of virus budding is one of the principal mechanisms of antiviral activity of M2-specific antibodies and that anti-M2 antibody-sensitive and -resistant IAVs have different properties in the interaction between M2 and HA. Although the IAV HA is the major target of neutralizing antibodies, most of the antibodies are HA subtype specific, restricting the potential of HA-based vaccines. On the contrary, the IAV M2 protein has been studied as a vaccine antigen to confer cross-protective immunity against IAVs with multiple HA subtypes, since M2 is antigenically conserved. Although a number of studies highlight the protective role of anti-HA neutralizing and nonneutralizing antibodies, precise information on the molecular mechanism of action of M2-specific antibodies is still obscure. In this study, we found that an anti-M2 antibody interfered with the HA-M2 association, which is important for efficient budding of progeny virus particles from infected cells. The antiviral activity was IAV strain dependent despite the similar binding capacity of the antibody to M2, and, interestingly, HA was involved in susceptibility to the antibody. Our data provide a novel mechanism underlying antiviral activity of M2-specific antibodies.</description><subject>Amino Acids</subject><subject>Animals</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal - metabolism</subject><subject>Antibodies, Viral - immunology</subject><subject>Antibodies, Viral - pharmacology</subject><subject>Antiviral Agents - immunology</subject><subject>Antiviral Agents - pharmacology</subject><subject>Dogs</subject><subject>HEK293 Cells</subject><subject>Hemagglutinin Glycoproteins, Influenza Virus - metabolism</subject><subject>Humans</subject><subject>Influenza A virus - drug effects</subject><subject>Influenza A virus - genetics</subject><subject>Influenza A virus - immunology</subject><subject>Madin Darby Canine Kidney Cells</subject><subject>Mutation</subject><subject>Protein Binding - drug effects</subject><subject>Species Specificity</subject><subject>Vaccines and Antiviral Agents</subject><subject>Viral Matrix Proteins - chemistry</subject><subject>Viral Matrix Proteins - genetics</subject><subject>Viral Matrix Proteins - immunology</subject><subject>Viral Matrix Proteins - metabolism</subject><subject>Virus Release - drug effects</subject><issn>0022-538X</issn><issn>1098-5514</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkctLAzEQxoMoWh83z5KjB7dmkk2zvQil-Kj4OGhFvITZbKKRbbZudgv1r3fVKgoDMzC_-eZjhpB9YH0Anh2_LnyfAVcq4WyN9IANs0RKSNdJjzHOEymyxy2yHeMrY5Cmg3STbAnBpOQSeuRpRG-qhS3ptTUvGHyc0WkobF0ufXimo9D4ha-xpCPzWTVLWjmKgU6CK1sb3pE--LqN9Jond3NrvPPmayiviuUu2XBYRru3yjtkenZ6P75Irm7PJ-PRVWKkUE2ihgwQHGIxzKUdGIWQS-lSVyDLFXBUggmwqXNYZBIFKgOFGAiX51maMSt2yMm37rzNZ7YwNjSdYz2v_Qzrpa7Q6_-d4F_0c7XQSokuoBM4XAnU1VtrY6NnPhpblhhs1UbNUwmZlIMh79Cjb9TUVYy1db9rgOnPd-jLh4n-eofmrMMP_lr7hX_uLz4AI66Hkw</recordid><startdate>20201209</startdate><enddate>20201209</enddate><creator>Manzoor, Rashid</creator><creator>Eguchi, Nao</creator><creator>Yoshida, Reiko</creator><creator>Ozaki, Hiroichi</creator><creator>Kondoh, Tatsunari</creator><creator>Okuya, Kosuke</creator><creator>Miyamoto, Hiroko</creator><creator>Takada, Ayato</creator><general>American Society for Microbiology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7987-9884</orcidid></search><sort><creationdate>20201209</creationdate><title>A Novel Mechanism Underlying Antiviral Activity of an Influenza Virus M2-Specific Antibody</title><author>Manzoor, Rashid ; Eguchi, Nao ; Yoshida, Reiko ; Ozaki, Hiroichi ; Kondoh, Tatsunari ; Okuya, Kosuke ; Miyamoto, Hiroko ; Takada, Ayato</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c537t-7901a1faad9b5e6c7a1b55f4fda0b712a73031e4ffad85a3a7c1d363fbb8480e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Amino Acids</topic><topic>Animals</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal - metabolism</topic><topic>Antibodies, Viral - immunology</topic><topic>Antibodies, Viral - pharmacology</topic><topic>Antiviral Agents - immunology</topic><topic>Antiviral Agents - pharmacology</topic><topic>Dogs</topic><topic>HEK293 Cells</topic><topic>Hemagglutinin Glycoproteins, Influenza Virus - metabolism</topic><topic>Humans</topic><topic>Influenza A virus - drug effects</topic><topic>Influenza A virus - genetics</topic><topic>Influenza A virus - immunology</topic><topic>Madin Darby Canine Kidney Cells</topic><topic>Mutation</topic><topic>Protein Binding - drug effects</topic><topic>Species Specificity</topic><topic>Vaccines and Antiviral Agents</topic><topic>Viral Matrix Proteins - chemistry</topic><topic>Viral Matrix Proteins - genetics</topic><topic>Viral Matrix Proteins - immunology</topic><topic>Viral Matrix Proteins - metabolism</topic><topic>Virus Release - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Manzoor, Rashid</creatorcontrib><creatorcontrib>Eguchi, Nao</creatorcontrib><creatorcontrib>Yoshida, Reiko</creatorcontrib><creatorcontrib>Ozaki, Hiroichi</creatorcontrib><creatorcontrib>Kondoh, Tatsunari</creatorcontrib><creatorcontrib>Okuya, Kosuke</creatorcontrib><creatorcontrib>Miyamoto, Hiroko</creatorcontrib><creatorcontrib>Takada, Ayato</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Manzoor, Rashid</au><au>Eguchi, Nao</au><au>Yoshida, Reiko</au><au>Ozaki, Hiroichi</au><au>Kondoh, Tatsunari</au><au>Okuya, Kosuke</au><au>Miyamoto, Hiroko</au><au>Takada, Ayato</au><au>Heise, Mark T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Novel Mechanism Underlying Antiviral Activity of an Influenza Virus M2-Specific Antibody</atitle><jtitle>Journal of virology</jtitle><addtitle>J Virol</addtitle><date>2020-12-09</date><risdate>2020</risdate><volume>95</volume><issue>1</issue><issn>0022-538X</issn><eissn>1098-5514</eissn><abstract>Protective immunity against influenza A viruses (IAVs) generally depends on antibodies to the major envelope glycoprotein, hemagglutinin (HA), whose antigenicity is distinctive among IAV subtypes. On the other hand, the matrix 2 (M2) protein is antigenically highly conserved and has been studied as an attractive vaccine antigen to confer cross-protective immunity against multiple subtypes of IAVs. However, antiviral mechanisms of M2-specific antibodies are not fully understood. Here, we report the molecular basis of antiviral activity of an M2-specific monoclonal antibody (MAb), rM2ss23. We first found that rM2ss23 inhibited A/Aichi/2/1968 (H3N2) (Aichi) but not A/PR/8/1934 (H1N1) (PR8) replication. rM2ss23 altered the cell surface distribution of M2, likely by cross-linking the molecules, and interfered with the colocalization of HA and M2, resulting in reduced budding of progeny viruses. However, these effects were not observed for another strain, PR8, despite the binding capacity of rM2ss23 to PR8 M2. Interestingly, HA was also involved in the resistance of PR8 to rM2ss23. We also found that two amino acid residues at positions 54 and 57 in the M2 cytoplasmic tail were critical for the insensitivity of PR8 to rM2ss2. These findings suggest that the disruption of the M2-HA colocalization on infected cells and subsequent reduction of virus budding is one of the principal mechanisms of antiviral activity of M2-specific antibodies and that anti-M2 antibody-sensitive and -resistant IAVs have different properties in the interaction between M2 and HA. Although the IAV HA is the major target of neutralizing antibodies, most of the antibodies are HA subtype specific, restricting the potential of HA-based vaccines. On the contrary, the IAV M2 protein has been studied as a vaccine antigen to confer cross-protective immunity against IAVs with multiple HA subtypes, since M2 is antigenically conserved. Although a number of studies highlight the protective role of anti-HA neutralizing and nonneutralizing antibodies, precise information on the molecular mechanism of action of M2-specific antibodies is still obscure. In this study, we found that an anti-M2 antibody interfered with the HA-M2 association, which is important for efficient budding of progeny virus particles from infected cells. The antiviral activity was IAV strain dependent despite the similar binding capacity of the antibody to M2, and, interestingly, HA was involved in susceptibility to the antibody. Our data provide a novel mechanism underlying antiviral activity of M2-specific antibodies.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>33055251</pmid><doi>10.1128/jvi.01277-20</doi><orcidid>https://orcid.org/0000-0002-7987-9884</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-538X
ispartof Journal of virology, 2020-12, Vol.95 (1)
issn 0022-538X
1098-5514
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7737731
source MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Amino Acids
Animals
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - metabolism
Antibodies, Viral - immunology
Antibodies, Viral - pharmacology
Antiviral Agents - immunology
Antiviral Agents - pharmacology
Dogs
HEK293 Cells
Hemagglutinin Glycoproteins, Influenza Virus - metabolism
Humans
Influenza A virus - drug effects
Influenza A virus - genetics
Influenza A virus - immunology
Madin Darby Canine Kidney Cells
Mutation
Protein Binding - drug effects
Species Specificity
Vaccines and Antiviral Agents
Viral Matrix Proteins - chemistry
Viral Matrix Proteins - genetics
Viral Matrix Proteins - immunology
Viral Matrix Proteins - metabolism
Virus Release - drug effects
title A Novel Mechanism Underlying Antiviral Activity of an Influenza Virus M2-Specific Antibody
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T16%3A14%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Novel%20Mechanism%20Underlying%20Antiviral%20Activity%20of%20an%20Influenza%20Virus%20M2-Specific%20Antibody&rft.jtitle=Journal%20of%20virology&rft.au=Manzoor,%20Rashid&rft.date=2020-12-09&rft.volume=95&rft.issue=1&rft.issn=0022-538X&rft.eissn=1098-5514&rft_id=info:doi/10.1128/jvi.01277-20&rft_dat=%3Cproquest_pubme%3E2451855692%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2451855692&rft_id=info:pmid/33055251&rfr_iscdi=true